VOSTALLY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vostally, and when can generic versions of Vostally launch?
Vostally is a drug marketed by Rosemont Pharms and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in VOSTALLY is ramipril. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vostally
A generic version of VOSTALLY was approved as ramipril by WATSON LABS on October 24th, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VOSTALLY?
- What are the global sales for VOSTALLY?
- What is Average Wholesale Price for VOSTALLY?
Summary for VOSTALLY
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in VOSTALLY? | VOSTALLY excipients list |
| DailyMed Link: | VOSTALLY at DailyMed |
US Patents and Regulatory Information for VOSTALLY
VOSTALLY is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rosemont Pharms | VOSTALLY | ramipril | SOLUTION;ORAL | 219757-001 | Jul 23, 2025 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VOSTALLY
See the table below for patents covering VOSTALLY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 202103724 | ⤷ Start Trial | |
| United Kingdom | 2591389 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2020039262 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VOSTALLY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0265685 | SPC/GB98/047 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| 0265685 | 99C0001 | Belgium | ⤷ Start Trial | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
| 0265685 | C980030 | Netherlands | ⤷ Start Trial | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch